Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
Alhallak K, Sun J, Wasden K, Guenthner N, O'Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK. Alhallak K, et al. Leukemia. 2021 Aug;35(8):2346-2357. doi: 10.1038/s41375-021-01127-2. Epub 2021 Jan 21. Leukemia. 2021. PMID: 33479469 Free PMC article.
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Federico C, et al. Among authors: alhallak k. Nat Commun. 2020 Nov 27;11(1):6037. doi: 10.1038/s41467-020-19932-1. Nat Commun. 2020. PMID: 33247158 Free PMC article.
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK. de la Puente P, et al. Among authors: alhallak k. J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28. J Control Release. 2018. PMID: 29196043 Free PMC article.
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK. Sun J, et al. Among authors: alhallak k. Cancers (Basel). 2020 Jan 28;12(2):305. doi: 10.3390/cancers12020305. Cancers (Basel). 2020. PMID: 32012878 Free PMC article.
Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.
Federico C, Sun J, Muz B, Alhallak K, Cosper PF, Muhammad N, Jeske A, Hinger A, Markovina S, Grigsby P, Schwarz JK, Azab AK. Federico C, et al. Among authors: alhallak k. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1483-1494. doi: 10.1016/j.ijrobp.2020.11.052. Epub 2020 Nov 27. Int J Radiat Oncol Biol Phys. 2021. PMID: 33253820 Free PMC article.
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia.
Alhallak K, Sun J, Muz B, Jeske A, Yavner J, Bash H, Park C, Lubben B, Adebayo O, Achilefu S, DiPersio JF, Azab AK. Alhallak K, et al. Oncotarget. 2021 Sep 14;12(19):1878-1885. doi: 10.18632/oncotarget.28054. eCollection 2021 Sep 14. Oncotarget. 2021. PMID: 34548905 Free PMC article.
32 results